InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 44.71% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 8.98M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 8.98M.
Overvalued
The company’s latest PE is -0.98, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 23.13M shares, decreasing 1.93% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 32.63K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.28.